An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients

Trial Profile

An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs Pegunigalsidase alfa (Primary)
  • Indications Fabry's disease
  • Focus Adverse reactions
  • Sponsors Protalix Biotherapeutics
  • Most Recent Events

    • 09 Jan 2018 Status changed from recruiting to completed.
    • 03 Jan 2018 Argentina, Chile, Germany, Israel and Serbia were the planned locations as per results published in European Clinical Trials Database record.
    • 13 Feb 2017 Results from one-year follow up of patients will be presented at the 13th Annual WORLDSymposium 2017, according to a Protalix Biotherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top